DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma.
about
Genomic Changes in Normal Breast Tissue in Women at Normal Risk or at High Risk for Breast CancerCharacterization of DNA Methylation in Circulating Tumor CellsTWIST1 is expressed in colorectal carcinomas and predicts patient survivalGenome-wide mapping of Polycomb target genes unravels their roles in cell fate transitionsFrequent promoter hypermethylation of the APC and RASSF1A tumour suppressors in parathyroid tumours.Twist expression promotes migration and invasion in hepatocellular carcinoma.Hypermethylation of CDKN2A exon 2 in tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients.Unraveling breast cancer heterogeneity through transcriptomic and epigenomic analysis.Hypermethylated 14-3-3-sigma and ESR1 gene promoters in serum as candidate biomarkers for the diagnosis and treatment efficacy of breast cancer metastasisRASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA.Human mammary cancer progression model recapitulates methylation events associated with breast premalignancy.Array-based DNA methylation profiling for breast cancer subtype discrimination.Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis.Epigenome remodelling in breast cancer: insights from an early in vitro model of carcinogenesisPredictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy.Hypermethylation of tumor suppressor genes involved in critical regulatory pathways for developing a blood-based test in breast cancer.Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer.Promoter methylation and the detection of breast cancerThe promoter methylation status and mRNA expression levels of CTCF and SIRT6 in sporadic breast cancerIdentification and validation of highly frequent CpG island hypermethylation in colorectal adenomas and carcinomas.An epigenetic marker panel for recurrence risk prediction of low grade papillary urothelial cell carcinoma (LGPUCC) and its potential use for surveillance after transurethral resection using urineHeterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastasesRelationship between tumor DNA methylation status and patient characteristics in African-American and European-American women with breast cancerTargeted apc;twist double-mutant mice: a new model of spontaneous osteosarcoma that mimics the human diseaseEpigenetic alteration of p16 and retinoic acid receptor beta genes in the development of epithelial ovarian carcinoma.DNA-methylation profiling distinguishes malignant melanomas from benign nevi.Basal-like breast cancer displays distinct patterns of promoter methylationDNA methylation epigenotypes in breast cancer molecular subtypes.Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumorsMethylated genes in breast cancer: associations with clinical and histopathological features in a familial breast cancer cohort.Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer.Body mass and DNA promoter methylation in breast tumors in the Western New York Exposures and Breast Cancer Study.Aberrant promoter methylation of HIN-1 gene may contribute to the pathogenesis of breast cancer: a meta-analysis.Molecular drivers of lobular carcinoma in situ.Gene promoter hypermethylation in ductal lavage fluid from healthy BRCA gene mutation carriers and mutation-negative controls.Hormone Replacement Therapy, Likely Neither Angel Nor Demon.Promoter Methylation of the Retinoic Acid Receptor Beta2 (RARβ2) Is Associated with Increased Risk of Breast Cancer: A PRISMA Compliant Meta-Analysis.Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence.The mitogen-activated protein kinase phosphatase-1 (MKP-1) gene is a potential methylation biomarker for malignancy of breast cancer.Soy isoflavones have an antiestrogenic effect and alter mammary promoter hypermethylation in healthy premenopausal women
P2860
Q26738987-88CFBD2D-F12B-41E3-B2BF-4983EA169F60Q26778427-0684876F-7991-458B-9736-A56730EA7377Q28477528-59B0E783-BA32-4F0C-919E-503C139CDB91Q29614512-D5A6A3F3-7263-4ACB-952F-36904E42F4D2Q30979173-E0073333-15E7-4AE0-9EBD-4366300D144AQ33483712-1C3DC84C-38C4-4184-8444-E5C357EA4FF1Q33556583-7F8E5FEC-3305-49B8-B53B-9F069C874FBCQ33570282-EB978B7B-A4C0-46DE-A182-33A2C2DB8394Q33582678-B440EDED-9B46-4B9A-942B-A699AD4D41CDQ33591552-5E2E3372-C67D-4833-9D13-6F8950AB69E7Q33627196-9F14D730-A1CA-4D64-B797-FA3FDB461D08Q33689442-2E69584E-5BE7-41E3-8E61-A6C6E1B781A2Q33738694-03BD09F7-3CB1-425A-8A5F-D9F388059B92Q33739319-A0BCEA82-D1D2-424B-A70B-FA7087E2AB9BQ33796956-EF4F3BDE-4FC1-4ED7-8C27-3C341F1AE112Q33808960-AF94CA7F-CBE4-4473-AAA0-C60DEC890B5EQ33892868-0E2D52DE-B3E3-4547-8224-C2881AAB0462Q33911603-A667474A-473B-4CD8-AC01-390BB0F69C1FQ34088277-E2639B58-9BF3-4E6C-8011-0DE1F3FF9708Q34170505-92005265-FAC4-4D96-A956-8501474CB126Q34221765-330346BD-609C-4110-865E-226B8A6D7737Q34245828-9431BF8E-D6AD-4035-81CF-22E2BBCCD610Q34305047-E2A6306D-EECF-4CD9-8579-2297E364BCD6Q34398283-814D54C6-ED1E-4D86-B316-8C2066C918FBQ34423868-EA67AB70-7276-442A-8F24-A67F6E3038A8Q34775571-50EEA471-6E98-4031-B602-1E748A664B92Q34982503-E4A1A6F7-8BEE-4E79-A0FF-821C7A882688Q34989097-75DCFE3D-88C5-47FB-9388-B0B3217BA16BQ35008011-6A0FA254-8927-41AB-A55B-31B1FAF50600Q35050475-F6B6C6FC-041C-4535-9F63-E6A6A85E75FEQ35082784-0CB7B5E1-F222-451E-86DB-885425CD6219Q35163939-3299B2C2-3815-4254-82EA-7A97FFB83BD3Q35172269-8C72D23B-F819-4A11-B220-7E149B84C321Q35676504-A62F5F29-9BFC-444A-AB55-837D51019E1CQ35749369-4FA628F3-E861-475B-9BAC-475CB2679332Q35780539-47CCA85A-4F5C-4095-8D84-B99066BAF0ABQ35801560-95E1CE5F-41E5-4E22-A548-18525C52B466Q35841605-C5BB287A-228B-4EB7-A8A0-9946E039964EQ36005081-C3AA8E57-5A73-4C71-8429-CCBE0E257856Q36079644-C210F04F-1670-4F75-9736-67282C072BB9
P2860
DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma.
description
2003 nî lūn-bûn
@nan
2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
DNA methylation of RASSF1A, HI ...... sive lobular breast carcinoma.
@ast
DNA methylation of RASSF1A, HI ...... sive lobular breast carcinoma.
@en
DNA methylation of RASSF1A, HI ...... sive lobular breast carcinoma.
@nl
type
label
DNA methylation of RASSF1A, HI ...... sive lobular breast carcinoma.
@ast
DNA methylation of RASSF1A, HI ...... sive lobular breast carcinoma.
@en
DNA methylation of RASSF1A, HI ...... sive lobular breast carcinoma.
@nl
prefLabel
DNA methylation of RASSF1A, HI ...... sive lobular breast carcinoma.
@ast
DNA methylation of RASSF1A, HI ...... sive lobular breast carcinoma.
@en
DNA methylation of RASSF1A, HI ...... sive lobular breast carcinoma.
@nl
P2093
P356
P1476
DNA methylation of RASSF1A, HI ...... sive lobular breast carcinoma.
@en
P2093
Elizabeth Garrett
Ella Evron
Jyoti Mehrotra
Kornelia Polyak
Mary Jo Fackler
Megan McVeigh
Pedram Argani
Saraswati Sukumar
P304
P356
10.1002/IJC.11508
P577
2003-12-01T00:00:00Z